Simplicity Solutions LLC Invests $201,000 in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Simplicity Solutions LLC acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 44,987 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

Other institutional investors also recently made changes to their positions in the company. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 18.5% during the fourth quarter. Deltec Asset Management LLC now owns 2,443,607 shares of the biopharmaceutical company’s stock worth $10,898,000 after acquiring an additional 381,810 shares during the period. Legato Capital Management LLC bought a new stake in shares of Ocular Therapeutix during the fourth quarter worth approximately $667,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ocular Therapeutix by 350.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 7,152 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of Ocular Therapeutix by 96.4% during the third quarter. GSA Capital Partners LLP now owns 233,582 shares of the biopharmaceutical company’s stock worth $733,000 after acquiring an additional 114,629 shares during the period. Finally, Graham Capital Management L.P. bought a new stake in shares of Ocular Therapeutix during the third quarter worth approximately $299,000. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Ocular Therapeutix in a research note on Friday. Piper Sandler boosted their price target on Ocular Therapeutix from $10.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. JMP Securities reiterated a “market outperform” rating and issued a $24.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, April 16th. Bank of America assumed coverage on Ocular Therapeutix in a research note on Friday, February 9th. They issued a “buy” rating and a $15.00 price target for the company. Finally, StockNews.com cut Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Friday, April 5th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.60.

Ocular Therapeutix Stock Down 10.9 %

Shares of OCUL opened at $5.22 on Monday. Ocular Therapeutix, Inc. has a one year low of $2.00 and a one year high of $11.31. The company has a market cap of $775.85 million, a P/E ratio of -4.18 and a beta of 1.30. The company has a debt-to-equity ratio of 0.82, a current ratio of 6.66 and a quick ratio of 6.59. The firm has a 50 day simple moving average of $8.75 and a two-hundred day simple moving average of $5.33.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). Ocular Therapeutix had a negative net margin of 138.15% and a negative return on equity of 321.12%. The business had revenue of $14.80 million during the quarter, compared to the consensus estimate of $15.31 million. Research analysts forecast that Ocular Therapeutix, Inc. will post -0.68 EPS for the current fiscal year.

Insider Transactions at Ocular Therapeutix

In other news, insider Rabia Gurses Ozden sold 7,764 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total transaction of $38,431.80. Following the completion of the transaction, the insider now directly owns 92,767 shares in the company, valued at $459,196.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Rabia Gurses Ozden sold 7,764 shares of the company’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total transaction of $38,431.80. Following the completion of the transaction, the insider now directly owns 92,767 shares in the company, valued at $459,196.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Antony C. Mattessich sold 18,338 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $90,773.10. Following the transaction, the chief executive officer now owns 427,943 shares of the company’s stock, valued at $2,118,317.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,366 shares of company stock worth $194,862. Corporate insiders own 5.50% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.